NCT05763160View on ClinicalTrials.gov

An Open-label Study That Will Test a Second Treatment Session of RZL-012.

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 29, 2023

Primary Completion Date

July 30, 2023

Study Completion Date

October 20, 2023

Conditions
Submental Fat
Interventions
DRUG

RZL-012

Ready to use drug product for injection into the subcutaneous fat

Trial Locations (1)

10021

Luxurgery, Manhattan

All Listed Sponsors
lead

Raziel Therapeutics Ltd.

INDUSTRY

NCT05763160 - An Open-label Study That Will Test a Second Treatment Session of RZL-012. | Biotech Hunter | Biotech Hunter